Telix Pharmaceuticals Limited (TLPPF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in North Melbourne, VIC, Australia. Der aktuelle CEO ist Christian Behrenbruch.
TLPPF hat IPO-Datum 2019-07-25, 415 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $3.56B.
Telix Pharmaceuticals Limited is a radiopharmaceutical company developing molecularly targeted radiation products for cancer and rare diseases across Australia, Belgium, Japan, Switzerland, and the United States. The company's pipeline includes diagnostic and therapeutic candidates addressing significant unmet medical needs, with lead programs in metastatic castrate-resistant prostate cancer, renal cancer, glioblastoma, and bone marrow conditioning. Key assets in late-stage development include TLX591-CDx and TLX591 for prostate cancer, TLX250-CDx for kidney cancer, and TLX101-CDx for brain cancer, complemented by earlier-stage programs such as TLX592 for targeted alpha therapy and TLX599-CDx for prostate cancer imaging. Telix has established strategic partnerships with China Grand Pharmaceutical and Healthcare Holdings Limited, Mauna Kea Technologies, and Lightpoint Medical to advance its molecular imaging and therapeutic platform. Founded in 2015 and headquartered in North Melbourne, Australia, the company is focused on translating its targeted radiation technology into clinical solutions for oncology and rare disease indications.
